From Outside to Inside? Dose-Dependent Renal Tubular Damage After High-Dose Peptide Receptor Radionuclide Therapy in Rats Measured with In Vivo 99mTc-DMSA-SPECT and Molecular Imaging

2007 ◽  
Vol 22 (1) ◽  
pp. 40-49 ◽  
Author(s):  
Flavio Forrer ◽  
Edgar Rolleman ◽  
Magda Bijster ◽  
Marleen Melis ◽  
Bert Bernard ◽  
...  
Keyword(s):  
Molecular Imaging ◽  
Radionuclide Therapy ◽  
Peptide Receptor Radionuclide Therapy ◽  
High Dose ◽  
Tubular Damage ◽  
Renal Tubular Damage ◽  
Peptide Receptor ◽  
Renal Tubular ◽  
Dose Dependent

scholarly journals Indications of Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors: An Updated Review

2021 ◽  
Vol 10 (6) ◽  
pp. 1267
Author(s):  
Baptiste Camus ◽  
Anne-Ségolène Cottereau ◽  
Lola-Jade Palmieri ◽  
Solène Dermine ◽  
Florence Tenenbaum ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Radionuclide Therapy ◽  
Somatostatin Receptors ◽  
Peptide Receptor Radionuclide Therapy ◽  
Phase Iii ◽  
Treatment Modalities ◽  
High Dose ◽  
Double Dose ◽  
Peptide Receptor ◽  
Phase Iii Study

Radionuclide therapy for neuroendocrine tumors is a form of systemic radiotherapy that allows the administration of targeted radionuclides into tumor cells that express a large quantity of somatostatin receptors. The two most commonly used radio-peptides for radionuclide therapy in neuroendocrine tumors are 90Y-DOTATOC and 177Lu-DOTATATE. Radio-peptides have been used for several years in the treatment of advanced neuroendocrine tumors. Recently, the randomized Phase III study NETTER-1 compared177Lu-DOTATATE versus high-dose (double-dose) octreotide LAR in patients with metastatic midgut neuroendocrine tumors, and demonstrated its efficacy in this setting. Strong signals in favor of efficiency seem to exist for other tumors, in particular for pancreatic and pulmonary neuroendocrine tumors. This focus on radionuclide therapy in gastroenteropancreatic and pulmonary neuroendocrine tumors addresses the treatment modalities, the validated and potential indications, and the safety of the therapy.

scholarly journals In Vivo Instability of 177Lu-DOTATATE During Peptide Receptor Radionuclide Therapy

2020 ◽  
Vol 61 (9) ◽  
pp. 1337-1340
Author(s):  
Mark Lubberink ◽  
Helena Wilking ◽  
Amalia Öst ◽  
Ezgi Ilan ◽  
Mattias Sandström ◽  
...  
Keyword(s):  
Radionuclide Therapy ◽  
Peptide Receptor Radionuclide Therapy ◽  
Peptide Receptor

scholarly journals Effect of Peptide Receptor Radionuclide Therapy in Combination with Temozolomide against Tumor Angiogenesis in a Glioblastoma Model

Cancers ◽  
2021 ◽  
Vol 13 (19) ◽  
pp. 5029
Author(s):  
Sang Hee Lee ◽  
Ji Young Choi ◽  
Jae Ho Jung ◽  
In Ho Song ◽  
Hyun Soo Park ◽  
...  
Keyword(s):  
Tumor Angiogenesis ◽  
Radionuclide Therapy ◽  
Tumor Volume ◽  
Therapeutic Potential ◽  
Combined Therapy ◽  
Peptide Receptor Radionuclide Therapy ◽  
Treated Group ◽  
Peptide Receptor ◽  
Vehicle Treated Group

Cell adhesion receptor integrin avb3 is a promising biomarker for developing tumor-angiogenesis targeted theranostics. In this study, we aimed to examine the therapeutic potential of peptide receptor radionuclide therapy (PRRT) with 188Re-IDA-D-[c(RGDfK)]2 (11.1 MBq). The results showed that the tumor volume was significantly decreased by 81% compared with the vehicle-treated group in U87-MG xenografts. The quantitative in vivo anti-angiogenic responses of PRRT were obtained using 99mTc-IDA-D-[c(RGDfK)]2 SPECT and corresponded to the measured tumor volume. PRRT combined with temozolomide (TMZ) resulted in a 93% reduction in tumor volume, which was markedly greater than that of each agent used individually. In addition, histopathological characterization showed that PRRT combined with TMZ was superior to PRRT or TMZ alone, even when TMZ was used at half dose. Overall, our results indicated that integrin-targeted PRRT and TMZ combined therapy might be a new medical tool for the effective treatment of glioblastoma.

Sign in / Sign up

Export Citation Format

Share Document